<DOC>
	<DOCNO>NCT01281553</DOCNO>
	<brief_summary>The purpose study compare efficacy tolerability cisapride placebo infant child gastro-oesophageal reflux disease ( GORD ) .</brief_summary>
	<brief_title>A Study Cisapride Patients With Symptomatic Gastro-Oesophageal Reflux Disease</brief_title>
	<detailed_description>This double-blind ( neither patient study staff know identity assign treatment ) study evaluate effectiveness safety cisapride patient gastro-oesophageal reflux disease ( GORD ) ( also refer gastroesophageal reflux disease [ GERD [ ) compare placebo ( identical appearance cisapride contain active drug ) . Patients receive placebo cisapride suspension 0.2 mg/kg ( volumn determine patient weight ) four time per day ( q.i.d . ) ( 15 minute feed 3 time day bedtime ) orally ( mouth ) 8 week .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Cisapride</mesh_term>
	<criteria>Diagnosis GORD base protocolspecified characteristic Failed 1st 5 stepwise treatment GORD recommend European Society Pediatric Gastroenterology , Hepatology Nutrition ( ESPGHAN ) Caregiver able complete IGERQR questionnaire Protocolspecified respiratory condition require previous current treatment oral intravenous corticosteroid ( prior concurrent use inhale corticosteroid acceptable ) Cause vomiting/regurgitation GORD Prior history cisapride intake</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Cisapride ( PREPULSID )</keyword>
	<keyword>Placebo</keyword>
	<keyword>Gastroesophageal Reflux Disease ( GERD )</keyword>
	<keyword>Gastro-oesophageal Reflux Disease ( GORD )</keyword>
</DOC>